Preferred Perspectives is a periodic one-hour national webinar hosted by Senior Vice President of Product Development and Marketing, Mark Pew. These webinars will cover subjects that are highly applicable to workers’ compensation and related industries. Each webinar is free to attend—no CE credits will be offered.
Browse below to look at past webinar’s and to register for future ones.
With all of this news coverage on the high price of prescription drugs, and the roles that manufacturers, pharmacies, and PBM’s play in that pricing, have you ever wondered how the money flows? Who sets those prices? And how many stops these drugs make on the supply chain before they actually get into the pocket of the consumer? And why is it that generic drugs made up 89% of all prescriptions filled in the U.S. last year, but only accounted for 26% of total drug costs? Scott E. Yasko, our Director of Project Management, will attempt to answer these questions and more in his session entitled “Follow the Money Pill Road: The Life Cycle of a Prescription Drug.” He will focus on the supply chain economics of the prescription drug industry to shed some light on an industry that many view as opaque and confusing.
David Price, our Director of Government Affairs, has had a front row seat to the evolution of drug formularies in workers’ compensation since 2013. He has not just been part of the discourse with regulators but has even helped shape the ways that formularies have been implemented in certain states. He has also worked with private sector companies – including payers, TPAs, PBMs, and utilization review organizations – to help them implement formularies in a way that both meets the requirements of the agencies involved and ensures quality and cost-effective treatment of injured workers. Through that experience, he has identified some policies that should be considered best practices and have been commonly incorporated into existing drug formularies. He has also seen where mistakes in drafting or implementing a formulary can lead to stakeholder confusion, delays of care, burdensome litigation, and penalties. As formularies continue to shape the way that medications are provided to injured workers, it is important to get them right, so hear his opinion on how that can be done.
Mark Pew, our Senior Vice President of Product Development and Marketing, has been reporting from the front lines of the medical marijuana evolution in work comp (reimbursement) and greater society (state legalization) since 2014. That means his opinions are well informed by time, research and conversations around the country. Part of that evolution has been the recent subtle change from the relatively vague term of “medical marijuana” to more specifically CBD (cannabidiol) in the treatment of pain and anxiety. In his opinion, the change from a psychoactive drug often used recreationally to one specific phytocannabinoid has implications to the overall conversation.